How many insider trades does FilingIQ track for ARTV?

FilingIQ tracks 100 Form 4 insider transactions for ARTV (Artiva Biotherapeutics, Inc.), covering filings from Jul 22, 2024 onwards. 13 of those were filed in the last 90 days.

Are ARTV insiders net buyers or net sellers?

Across the full Form 4 history for ARTV, 10 transactions (10%) were open-market purchases and 4 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ARTV insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ARTV in?

Artiva Biotherapeutics, Inc. (ARTV) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $101.86M.

ARTV insider trading

NasdaqGM Healthcare

Artiva Biotherapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

100

Last 90 days

Buys / sells

10% / 4%

Market cap

$101.86M

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Company website: www.artivabio.com

ARTV insider activity at a glance

FilingIQ has scored 100 insider transactions for ARTV since Jul 22, 2024. The most recent filing in our index is dated May 11, 2026.

Across the full history, 10 open-market purchases and 4 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ARTV insider trades is 53.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ARTV trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for ARTV?: FilingIQ tracks 100 Form 4 insider transactions for ARTV (Artiva Biotherapeutics, Inc.), covering filings from Jul 22, 2024 onwards. 13 of those were filed in the last 90 days.
Are ARTV insiders net buyers or net sellers?: Across the full Form 4 history for ARTV, 10 transactions (10%) were open-market purchases and 4 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ARTV insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ARTV in?: Artiva Biotherapeutics, Inc. (ARTV) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $101.86M.

Methodology & sources

Every ARTV insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.